Printer Friendly

-Vitrolife, ParentPlus to collaborate on artificial insemination products.

M2 EQUITYBITES-November 11, 2011--Vitrolife, ParentPlus to collaborate on artificial insemination products(C)2011 M2 COMMUNICATIONS

11 November 2011 - Swedish medical technology company Vitrolife AB (STO:VITR) unveiled today an agreement with US ParentPlus LLC to co-develop new products for intrauterine insemination (IUI), a method of artificial insemination.

According to Vitrolife, the IUI market is estimated at about 4m-6m treatments a year, with a market value of between SEK1bn and SEK2bn.

So far, the Swedish company has been mostly active in the area of in vitro fertilisation (IVF). In many countries patients are required to undergo IUI treatment before resorting to IVF.

(EUR1 = SEK9)

((Comments on this story may be sent to

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Nov 11, 2011
Previous Article:-Peab receives SEK264m contract in northern Sweden.
Next Article:-Gazprombank reportedly launches CHF350m bond, yield seen at 4.38%.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters